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ABSTRAK 
Pengesanan kekurangan zat besi dalam pesakit yang menghidap penyakit anemia kronik 
adalah tidak mudah. Ini adalah kerana, ujian makmal untuk mengesan status zat besi 
yang selalu digunakan dipengaruhi oleh tindakbalas akut. Tujuan kajian ini adalah untuk 
mengetahui kekerapan kekurangan zat besi dalam pesakit yang menghidap penyakit 
anemia kronik menggunakan pelbagai ujian hematologikal dan membandingkan 
keputusan dengan kontrol. 
Seramai 60 pesakit yang disahkan menghidap penyakit anemia kronik dan seramai 25 
kontrol terdiri daripada sukarelawan yang sihat yang bekerja di HUSM diambil untuk 
menyertai kajian ini. Kedua-dua kumpulan haruslah memenuhi syarat-syarat 
pengambilan dan pengecualian sebelum diuji untuk mengetahui status zat besi. Ujian-
ujian yang dijalankan termasuklah gambaran keseluruhan sel-sel darah, ferritin, penerima 
transferrin dan indeks penerima transferrin- ferritin. 
Keputusan menunjukan tiada seorang daripada kumpulan kontrol yang ada kekurangan 
zat besi. Kekurangan zat besi dalam pesakit yang ada anemia kronik dikesan sebanyak 
20% menggunakan penerima transferrin, 16.7% menggunakan indeks penerima 
transferrin-ferritin dan tiada kes yang dikesan oleh ferritin. Kekurangan yang signifikan 
ditemui dari segi purata isipadu sel darah dan ferritin tetapi nilai yang lebih tinggi yang 
signiftkan dalam ujian penerima transferrin dan keluasan pengagihan sel darah merah 
yang dibandingkan diantara pesakit penyakit anemia kronik dan kontrol 
IX 
Didapati terdapat kekurangan yang siginifikan dari segi purata isipadu sel darah, purata 
kepekatan sel hemoglobin dan ferritin, nilai lebih tinggi yang juga signifikan dari segi 
ujian penerima transferrin dan keluasan pengagihan sel darah merah yang dibandingkan 
diantara pesakit yang ada kekurangan zat besi dan yang tiada dalam kumpulan penyakit 
anemia kronik. 
Penemuan yang tersebut menunjukan profil anemia disebabkan oleh kekurangan zat besi 
dan menyokong kemungkinan adanya kekurangan zat besi dalam pesakit penyakit anemia 
kronik. 
Tiada perbezaan yang signifikan didalam purata penerima transferrin di antara lelaki dan 
perempuan dalam kumpulan kontrol. Walaubagaimanapun, terdapatnya pertalian yang 
Iemah apabila membandingkan umur dan sukatan penerima transferrin. 
Kesimpulannya, terdapat sebahagian pesakit penyakit anemia kronik yang ada 
kekurangan zat besi dan pengetahuan tentang kewujudan ini adalah berguna kerana ia 
boleh menolong dalam pengurusan pesakit-pesakit ini. 
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ABSTRACT 
Detecting iron deficiency anaemia (IDA) in anaemia of chronic disease (ACD) patients is 
not easy, as the conventional laboratory indices of iron status are often influenced by 
acute phase responses. The aim of the study is to determine the prevalence of iron 
deficiency in ACD patients using various haematological tests and to compare with the 
normal control. 
Sixty ACD patients were purposively recruited while 25 controls were healthy volunteers 
among the HUSM staffs. Both groups had to fulfill their inclusion and exclusion criteria 
before they were tested to determine the iron status. Investigations for iron status 
consisted of full blood picture with other haematological indices, serum ferritin, soluble 
transferrin receptor (sTfR) and Transferrin receptor-ferritin index (TfR-F index). 
Results showed that none of the controls were having iron deficiency anaemia. 
Coexisting IDA in ACD group were detected 20% by sTfR, 16.7% by TfR-F index and 
none using serum ferritin. There were significantly lower mean corpuscular volume 
(MCV) and serum ferritin but higher for red cell distribution width (RDW) and sTfR. in 
ACD group compared to the normal controls (P<O.OOl) 
Comparing IDA cases and the non-IDA cases in the ACD group, there were significantly 
lower mean corpuscular volume (MCV),mean cell haemoglobin concentration (MCHC) 
and serum ferritin but higher for red cell distribution width (RDW) and sTtR (P<O.OOl), 
The findings above pointed towards "IDA-like" profile and support the possibility of co-
existing iron deficiency anaemia. The mean sTtR level was not significantly different 
between males and females in the control group. However, a weak correlation was noted 
between age and sTfR levels. 
In conclusion, a proportion of ACD patients had coexisting IDA and knowing this 
coexistence will be beneficial, as it will assist in better management of these patients. 
Xl 
CHAPTER I 
GENERAL INTRODUCTION 
1.0 GENERAL INTRODUCTION 
Iron deficiency is a common clinical problem. In many cases, iron deficiency is relatively 
simple to diagnose. However, in some patients with many medical problems, such as 
malignancy, infection, inflammation, the diagnosis can be difficult (Weiss and 
Goodnough, 2005). 
Serum iron, total iron binding capacity (TffiC), transferrrin saturation and serum ferritin 
are the conventional laboratory tests to assess iron status. These tests are however 
influenced by inflammatory acute phase reactions, which may complicate the clinical 
interpretation of the tests results (Fitzsimons et al, 2001 ). 
The detection of iron deficiency in the presence of chronic disease is an important 
diagnostic challenge because of the frequency of the problem seen in clinical practice and 
its direct implication on the patient management (Weiss and Goodman, 2005). 
In anaemia of chronic disease (ACD) inappropriate iron therapy may aggravate the 
underlying disease (Vreugdenhil et a/, 1990).Because the absence of stainable iron in the 
bone marrow examination is generally regarded as the definitive marker of iron 
deficiency, marrow examinations are generally requested to confrrm iron deficiency. This 
method is invasive and not convenient ( Punnonen et al, 1997) 
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There is an evident clinical need for non invasive and sensitive method for detection of 
iron deficiency, and in recent years, the serum transferrin receptor (sTtR) level has been 
introduced as a new tool for the diagnosis of iron depletion (Cook, 2005). 
Serum transferrin receptor is largely determined by the quantum of erythropoeisis and by 
intracellular iron content of the cells of the erythroid lineage (Gupta et a/, 2003). Most 
importantly, it is not an acute phase reactant, and remains normal in patients with 
inflammatory conditions (Skikne, 1998). Hence, it could serve as a better indicator for the 
existence of iron deficiency in ACD. 
In the previous study, transferrin receptor-log ferritin ratio, the TtR.-F index, was used 
because it was shown to improve the diagnostic efficiency for IDA compared with serum 
sTfR level alone or the sTtR-ferritin ratio. The TtR-F index is an accurate marker for 
IDA, because it represents the total-body iron stores and the availability of iron for 
erythropoiesis. A positive finding on the TfR-F index (>2) can accurately establish a 
diagnosis of IDA and may eliminate the need for bone marrow e~amination (Weiss and 
Goodnough, 2005) 
I hope that this study will contribute to a better comprehension of the problem and will 
help to find the ideal way of detecting coexisting iron deficiency in anaemia of chronic 
disease patients. 
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CHAPTER2 
LITERATURE REVIEW 
2.0 LITERATURE REVIEW 
2.1 moN METABOLISM 
2.1.1 Introduction 
Iron is the fourth most abundant terrestrial element, comprising approximately 4. 7% of 
the earth's crust in the fonn of the minerals hematite, magnetite, and siderite. Despite its 
abundance in the earth's crust, iron deficiency is a serious health issue in many parts of 
the world. The iron nutrition status of an individual and of populations is largely a 
function of the amount of dietary iron, the bioavailability of that iron, and the extent of 
iron losses. Heme iron is an important dietary source of iron because it is more 
effectively absorbed than nonheme iron. From 5% to 35% of heme iron is absorbed from 
a single meal, whereas nonheme iron absorption from a single meal can range from 2% to 
20% (Pietrangelo, 2001) 
2.1.2 Iron Absorption 
The majority of iron absorption takes place in the duodenum and upper jejunum. The 
process of iron absorption can be divided into three stages: (1) iron uptake, (2) 
intraenterocyte transport, and (3) storage and extraenterocyte transfer. During the 
intestinal phase of digestion, iron binds to specific mucosal membrane sites, is 
internalized, and then either is retained by the mucosal cell or is transported to the 
basolateral membrane where it is bound to transferrin (Tf) in the plasma pool. The 
process of iron absorption is controlled by intraluminal, mucosal, and somatic factors. A 
multitude of intraluminal factors affect the amount of iron available for absorption as 
either inhibitors or promoters. Mucosal factors include the amount of mucosal surface 
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and intestinal motility. Somatic factors that influence iron absorption include 
erythropoiesis and hypoxia (Roy et a/, 2000) 
Hemoglobin and serum ferritin apparently have limited roles in signaling the enterocyte 
about the need for iron absorption. It has been suggested that internalized plasma ferro-Tf 
may allow the enterocyte to monitor body iron status and regulate iron absorption. 
Exposure to low intracellular amounts of plasma ferro-Tf would signal the enterocyte to 
up-regulate iron entry into the body. Transferrin receptors (TfR) are only found at the 
basolateral surface of enterocytes. The amount of enterocyte TfR mRNA and protein 
increases during iron deficiency and decreases during secondary iron loading. Acute 
hemolysis, which stimulates iron absorption, does not influence enterocyte basolateral 
TfR number (Pietrangelo, 2001 ). 
Active erythropoiesis, induced either by bleeding or by acute hemolysis increases the 
absorption of iron. It has therefore been proposed that erythropoietin is an endogenous 
signal for iron absorption; there is limited evidence for this hypothesis. Hypoxia increases 
iron absorption independently of erythropoiesis (Cavill, 2002). Increased plasma iron 
turnover, which occurs not only in erythropoiesis but also in disorders of ineffective 
erythropoiesis such as thalassemia, hemolytic anemias, and sideroblastic anemias, is 
associated with increased iron absorption. Other clinical disorders such as 
hemochromatosis, congenital ferrochelatase deficiency, and porphyria cutanea tarda 
result in an increased iron absorption by mechanisms that are yet unexplained. Finally, 
inflammatory processes may decrease iron absorption,' probably by eliciting the 
production of cytokines that have a direct effect on the mucosal cell (Roy et a/, 2000). 
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2.1.3 Iron transport and storage 
The most significant iron transport molecule is transferrin. A number of other systems 
may make small but important contributions in transporting iron to the tissues including 
heme-hemopexin (HPX), ferritin and lactofenin (Pietrangelo, 2001 ). 
The concentration of iron in the human body is approximately 30-40 mg/kg body weight. 
However, that concentration varies as a function of age and gender and the specific 
tissues and organs examined. About 85-90% of nonstorage iron is found in the erythroid 
mass. The storage iron concentration in the body varies from 0 to 15 mglkg body weight 
depending on gender and iron status. The distribution of this stored iron is not uniform, as 
the liver contains approximately 60% of the ferritin in the body. The remaining 40% is 
found in muscle tissues and cells of the reticuloendothelial system. Normally, 95% of the 
stored iron in liver tissue is found in hepatocytes as ferritin. Hemosiderin constitutes the 
remaining 5% and is found predominately in Kupffer cell lysosomal remnants. However, 
during iron overload, the mass of hemosiderin in the liver accumulates at 10 times the 
rate of ferritin (Bastin et al, 1998). 
Most cellular iron acquisition occurs via TfR uptake. The functional receptor is 
composed of two monomers, linked by two disulfide bridges. Virtually all cells, except 
mature red cells, have TfR on their surface, but the largest numbers are in the erythron, 
placenta and liver. In a normal adult, about 80% are in the erythroid marrow. Receptor 
density on proliferating cells is related to the availability of iron as deprivation of iron 
results in prompt induction of TfR synthesis whereas excess iron suppresses TfR 
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numbers. Hence, the total mass of cellular TfR depends both on the number of erythroid 
precursors in the bone marrow and on the number of TfR per cell, a function of iron 
status of the cell (Beguin, 2003). 
A circulating form ofTfR has been found in human as well as animal serum. Serum TfR 
(sTfR) is a soluble truncated monomer of tissue receptor, lacking its first 100 amino acid, 
which circulates in the form of transferrin and its receptor. STfR is produced by 
proteolysis, mediated by a membrane - associated serine protease that occurs mostly at 
the surface of exosomes (Shih et al, 1990) 
2.2 ERYTHROPOIESIS AND IRON 
Iron and erythropoeisis are inextricably linked. Erythropoeisis is a dynamic process that 
requires 30-40 mg iron each day to be supplied to the developing erythroblasts. This is a 
highly dynamic process based on the delicate balance between iron demand and supply. 
The major source of large amount of iron that the developing red cells require is 
delivered by transferrin which is received by the transferrin receptor on the surface of 
erythroblast (Cavill, 2002). The amount of iron required by the developing erythroblasts 
is some I 0-fold greater than the total amount of iron circulating in the transferrin iron 
pool at any one time. Hence, this pool turnover 10 or more times each day and an iron 
atom entering that pool will only spend ninety minutes in the circulation before being 
taken up by the marrow. The transient balance between inflow and outflow is easily 
disturbed and this accounts for the biological lability of that pool (Pietrangelo, 2001 ). 
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In normal circumstances daily red cell production is balanced by equal red cell 
destruction. This releases sufficient iron to maintain haemoglobin (Hb) synthesis at its 
previous level. 
It is established that the positive feedback control mechanism of hypoxia, erythropoietin 
secretion and haemoglobin concentration are the determinants of erythropoietic activity. 
It is evident that other mechanisms may also play a part. In normal subjects with no 
obvious hypoxic problems, it was shown that some marrows would produce red cells at 
twice the rate of others. In a fully compensated haemolysis, where red cells production 
are many times the normal level, the absence of hypoxic stimulus does not lead to any 
increase in erythropoietin secretion (Kendall, 2001) 
The balance of red cell production and destruction maintains the haemoglobin 
concentration. When production fails to keep pace with destruction then there will be a 
gradual diminution in the Hb concentration until this reaches some arbitrary level that is 
considered to indicate anaemia (Cavill, 2002). 
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2.3 ANAEMIA OF CHRONIC DISEASE 
2.3.1 Definitions 
Anaemia of chronic disease (ACD) is the second most prevalent after anaemia caused by 
iron deficiency, occurs in patients with acute or chronic immune activation (Weiss, 
2002). 
The most frequent conditions associated with anemia of chronic disease are acute and 
chronic infections, inflammatory, neoplastic, chronic kidney disease and inflammatory 
diseases (Weiss, 2002). Syndromes similar or identical to ACD are also observed in 
intensive care units, in post-surgical setting and following severe trauma (Means, 2004) 
The diagnosis of ACD is quite easy and based on the underlying disturbances of iron 
homeostasis which lead to withdrawal of the metal from the sites of erythropoeisis and 
the circulation to the storage compartment in the reticuloendothelial system thus causing 
at the same time hypoferraemia and hyperferritinaemia (Weiss, 2002). 
They are usually of moderate severity with high haemoglobin (Hb) concentration ranging 
from 7 to llg/dl. They are associated with a low serum iron, a low iron-binding capacity, 
increased tissue iron stores and a reduced rate of red cell production (Fitzsimons et al, 
2001) 
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2.3.2 Pathophysiological features 
i. Introduction 
ACD is immune driven. Cytokines and cells of the reticuloendothelial system induce 
changes in iron homeostasis, the proliferation of erythroid progenitor cells, the 
production of erythropoietin, and the life span of red cells, all of which contribute to the 
pathogenesis of anaemia (Weiss et al, 2005). 
Erythropoiesis can be affected by disease underlying anemia of chronic disease through 
the infiltration of tumor cells into bone marrow or of microorganisms, as seen in human 
immunodeficiency virus (HIV) infection, hepatitis C, and malaria (Gordeuk et al, 2001). 
Moreover, tumor cells can produce proinflammatory cytokines and free radicals that 
damage erythroid progenitor cells. Bleeding episodes, vitamin deficiencies (e.g., of 
cobalamin and folic acid), hypersplenism, autoimmune hemolysis, renal dysfunction, and 
radio- and chemotherapeutic interventions themselves can also aggravate anemia 
(Groopman, 1999). 
Anaemia with chronic kidney disease shares some of the characteristics of anemia of 
chronic disease, although the decrease in the production of erythropoietin, mediated by 
renal insufficiency and the antiproliferative effects of accumulating uraemic toxins, 
contribute importantly. In addition, in patients with end-stage renal disease, chronic 
immune activation can arise from contact activation of immune cells by dialysis 
membranes, from frequent episodes of infection, or from both factors, and such patients 
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present with changes in the homeostasis of body iron that is typical of anemia of chronic 
disease (Eschbach et a/, 2002) 
ii. Disturbances in Iron Homeostasis 
A hallmark of anaemia of chronic disease is the development of disturbances of iron 
homeostasis, with increased uptake and retention of iron within cells of the 
reticuloendothelial system. This leads to a diversion of iron from the circulation into 
storage sites of the reticuloendothelial system, subsequent limitation of the availability of 
iron for erythroid progenitor cells, and iron-restricted erythropoiesis (Weiss et al, 2005). 
In mice that are injected with the proinflammatory cytokines interleukin-1 and tumor 
necrosis factor a (TNF-a), both hypoferremia and anemia develop; this combination of 
conditions has been linked to cytokine-inducible synthesis of ferritin, the major protein 
associated with iron storage, by macrophages and hepatocytes (Torti et a/, 2002). In 
chronic inflammation, the acquisition of iron by macrophages most prominently takes 
place through erythrophagocytosis and the transmembrane import of ferrous iron by the 
protein divalent metal transporter 1 (DMT-1) (Andrews, 1999) 
IFN-y (lnterferon-y}, lipopolysaccharide, and 1NF-a upregulate the expression of DMT-
1, with an increased uptake of iron into activated macrophages. These proinflammatory 
stimuli also induce the retention of iron in macrophages by down-regulating the 
expression of ferroportin, thus blocking the release of iron from these cells (Torti eta/, 
2002). Ferroportin is a transmembrane exporter of iron, a process that is believed to be 
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responsible for the transfer of absorbed ferrous iron from duodenal enterocytes to the 
circulation. Moreover, antiinflammatory cytokines such as interleukin-1 0 can induce 
anaemia through the stimulation of transferrin-mediated acquisition of iron by 
macrophages and by translational stimulation of ferritin expression (Tilg et al, 2002). 
The identification of hepcidin, an iron-regulated acute-phase protein that is composed of 
25 amino acids, helped to identify the relationship of the immune response to iron 
homeostasis and anemia of chronic disease Hepcidin expression is induced by 
lipopolysaccharide and interleukin-6 and is inhibited by 1NF-a. Transgenic or 
constitutive overexpression of hepcidin results in severe iron-deficiency anemia in mice 
(Nicolas et al, 2002). Inflammation in mice that are hepcidin-deficient did not lead to 
hypoferremia, a finding that suggests that hepcidin may be centrally involved in the 
diversion of iron traffic through decreased duodenal absorption of iron and the blocking 
of iron release from macrophages that occurs in anemia of chronic disease The induction 
of hypoferremia by interleukin-6 and hepcidin occurs within a few hours and is not 
observed in interleukin-6-knockout mice that are treated with turpentine as a model of 
inflammation, a finding that suggests that hepcidin may be central to anemia of chronic 
disease (Nemeth eta/, 2004). A recently identified gene, hemojuvelin, may act in concert 
with hepcidin in inducing these changes. Accordingly, the disturbance of iron 
homeostasis with subsequent limitation of the availability of iron for erythroid progenitor 
cells appears to impair the proliferation of these cells by negatively affecting heme 
biosynthesis (Andrews, 2004). 
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iii.Impaired proliferation of erythroid progenitor cells 
The proliferation and differentiation of erythroid precursors - erythroid burst-forming 
units and erythroid colony-forming units are impaired and are due to the inhibitory 
effects of interferon-a, -P, and-y, TNF-a, and interleukin-l.These cytokines influence the 
growth of erythroid burst-forming units and erythroid colony-forming units. Interferon-"( 
appears to be the most potent inhibitor of erythropoiesis in directly blocking colony 
forming unit proliferation. This notion is reflected by an inverse correlation with 
hemoglobin concentrations and reticulocyte counts (Weiss, 2002). The underlying 
mechanisms may involve cytokine-mediated induction of apoptosis, which appears, in 
part, related to the formation of ceramide, the down-regulation of the expression of 
erythropoietin receptors on progenitor cells, impaired formation and activity of 
erythropoietin, and a reduced expression of other prohematopoietic factors, such as stem-
cell factor .Moreover, cytokines exert direct toxic effects on progenitor cells by inducing 
the formation of labile free radicals such as nitric oxide or superoxide anion by 
neighboring macrophage-like cells (Means, 2004) 
iv. Blunted erythropoietin response 
Erythropoietin regulates erythroid-cell proliferation centrally. Erythropoietin expression 
is inversely related to tissue oxygenation and haemoglobin levels, and there is a 
semilogarithmic relation between the erythropoietin response (log) and the degree of 
anaemia (linear). Erythropoietin responses in anaemia of chronic disease are inadequate 
for the degree of anaemia in most, but not all, conditions (Cazzola et a/, 1996) 
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The cytokines interleukin-1 and TNF-a directly inhibit erythropoietin expression in vitro, 
a fmding that is probably due, at least in part, to cytokine-mediated formation of reactive 
oxygen species, which in tum affects the binding affinities of erythropoietin-inducing 
transcription factors and also damages erythropoietin-producing cells. Although 
convincing data from human studies are lacking, the injection of lipopolysaccharide into 
mice results in reduced expression of erythropoietin mRNA in kidneys and decreased 
levels of circulating erythropoietin (Jelkmann, 1998). 
The responsiveness of erythroid progenitor cells to erythropoietin appears to be inversely 
related to the severity of the underlying chronic disease and the amount of circulating 
cytokines, since in the presence of high concentrations of interferon-y or TNF -a, much 
higher amounts of erythropoietin are required to restore the formation of erythroid 
colony-forming units. After binding to its receptor, erythropoietin stimulates members of 
the signal transduction pathways and subsequently activates mitogen and tyrosine kinase 
phosphorylation, processes affected by the inflammatory cytokines and the negative-
feedback regulation they induce (Minoo et al, 2004). 
The response to erythropoietin is further reduced by the inhibitory effects of 
proinflammatory cytokines toward the proliferation of erythroid progenitor cells, the 
parallel down-regulation of erythropoietin receptors, and the limited availability of iron to 
contribute to cell proliferation and hemoglobin synthesis. Finally, increased 
erythrophagocytosis during inflammation leads to a decreased erythrocyte half-life, along 
with anticipated damage to erythrocytes that is mediated by cytokines and free radicals 
(Spivak, 2002). 
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2.4 IMPAIRMENT OF IRON STATUS 
2.4.1 Introduction. 
A requirement for analysis and determination of iron status is the detection of all phases 
of developing iron deficiency. Real iron deficiency is to be correctly differentiated from 
ACD. However, in some cases the ACD can coexist with iron deficiency state which 
makes the laboratory evaluation of the iron status difficult. It is important to identify iron 
deficiency state in the patients with ACD as this determines subsequent management of 
the patients. 
2.4.2 Dermitions of impaired iron status. 
Iron deficiency is defined as a reduction in total body iron to an extent that iron stores are 
fully exhausted and some degree of tissue iron deficiency is present. 
Iron deficiency develops slowly in three stages; storage iron deficiency, iron deficiency 
erythropoiesis (IDE) and iron deficiency anaemia (IDA) (Cook, 2005) 
Iron deficient erythropoiesis refers to impaired supply of plasma iron to the erythroid 
marrow for haemoglobin synthesis, either directly as a reduced iron saturation of plasma 
transferrin, or indirectly as signs of iron deficiency in circulating red blood cells 
(W orwood, 1997) 
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IDE is a cardinal feature of iron deficiency anaemia but it can also be seen in other 
clinical disorders associated with inflammation or malignancy. Iron store are totally 
absent in IDA, whereas IDE can occur with normal or increased amounts of storage iron 
resulting from impaired release of iron to the plasma from the storage iron compartment. 
Functional iron deficiency is a specific form of IDE seen in patients given recombinant 
human erythropoietin, a treatment that exaggerates any disparity between the influxes of 
iron to the plasma from the storage compartment and the iron requirements erythroid 
marrow (Thomas et al, 2002). 
2.5 LABORATORY EVALUATION OF ANAEMIA OF CHRONIC DISEASE 
2.5.1 Screening measurements 
Screening measurements identify iron deficiency erythropoiesis by demonstrating either a 
reduced supply of plasma iron or poor haemoglobinization of circulating red blood cells. 
Haemoglobin is the first screening measurement and is measured as part of the complete 
blood count as mean cell haemoglobin (MCH) content and as mean cell haemoglobin 
concentration (MCHC) (Cook, 2005). 
In ACD, the haemoglobin level is normally moderately reduced (7-tlg/dl). However, it 
has low specificity and sensitivity for identifying iron deficiency. This is because there 
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are numerous other causes of anaemia that can mimic iron deficiency in the laboratory 
(Worwood, 1997). 
Screening measurements that identify IDE are helpful in reducing the diagnostic 
possibilities for IDA. Measurement of serum iron concentration provides little useful 
information because of the considerable variation from hour-to-hour and day-to-day in 
normal individuals. Low concentrations are found in patients with IDA and high 
concentrations in patients with iron overload. Low serum iron concentration can also be a 
response to inflammation, infection and surgery and does not necessarily indicate an 
absence of storage iron (Worwood, 1997). 
More information can be obtained by measuring both the serum iron concentration and 
the total iron binding capacity (TIBC), from which the percentage of transferrin 
saturation with iron may be calculated. Marked diurnal variation in plasma iron values 
and numerous clinical disorders that affect the transferrin saturation limit its clinical 
utility. Normal or elevated transferrin saturation is as useful for excluding IDA as low 
value is for identifying it (Cook et al, 2003). 
With the improved accuracy of measuring red-cell indices that resulted from the 
introduction of automated haematology analysers, the MCV became the most important 
red cell marker for detecting IDE It is a reliable and widely available measurement it is 
relatively late indicator in patients who are not actively bleeding. Thalassaemia must be 
considered in the differential diagnosis of a low MCV (Cook, 2005) 
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The percentage of circulating hypochromic erythrocytes permits earlier detection of IDE 
than the MCV, but a few weeks of IDE is required before the measurement becomes 
abnormal. 
A more rapid change occurs with the reticulocyte haemoglobin content (CHr) that falls 
within couple of days of the onset of IDE. Falsely normal CHr can be measured with an 
elevated MCV or thalassaemia (Thomas et al, 2002). 
Another simple and reliable method is the measurement of erythrocyte zinc 
protoporphyrin (ZPP), a product of abnormal haem synthesis (Labbe et al, 1999). The 
concentration increases in iron deficiency. The small sample size, simplicity, rapidity and 
reproducibility within the laboratory are advantages (Worwood, 1997). Chronic diseases 
that reduce serum iron concentration, but do not reduce iron stores, also increase 
protoporphyrin level. A significant limitation is that it increases with lead toxicity, and 
even the normal range varies with environmental lead (Cook et al, 2003) 
2.5.2 Storage iron 
The diagnosis of IDA requires evidence that iron stores are fully depleted. Bone marrow 
examination has been widely regarded the gold standard for the diagnosis. However, 
recent studies have shown that the marrow iron stain is often unreliable. It is also not 
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suitable to be done in clinical practice for the sole purpose of diagnosing IDA because of 
the expense, discomfort and the technical pitfalls of this approach (Cook, 2005). 
The serum ferritin has been the most useful laboratory measure of iron status which 
offers important advantages over bone marrow examination. A valuable feature of the 
measurement is that the concentration is directly proportional to body iron stores in 
healthy individuals. It is universally available, well standardized measurement and a level 
of::; 12-20JJ.g/l is a highly specific indicator of iron deficiency (Mast et al, 1998). Many 
studies have shown its superiority over other iron-related measurements for identifying 
IDA. Ferritin consists of H-and L-subunits. The H- subunits are regulated at the DNA 
level by cytokines and may act like a positive acute phase protein that increases in 
response to underlying infection and inflammation. In this context, serum ferritin does no 
longer reflect body iron stores when iron deficiency and ACD coexist, and its use may 
result in an underestimation of iron deficiency (Ahluwalia, 1998) 
2.5.3 Tissue iron 
The diagnosis of iron deficiency requires the demonstration of tissue iron deficiency. 
This can be demonstrated by examining the iron status of the erythroid marrow. The 
uptake of plasma iron by red-cell precursors is regulated by the transferrin receptor, a 
transmembrane glycoprotein that serves as the portal for the transferring iron to the 
interior of all body cells (Cook, 2005). 
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2.5.4 Soluble transferrin receptor and iron status 
Soluble form of the transferrin receptors (sTfR.) are detectable in the circulation by 
immunoassay and appear to reflect the number of transferrin receptors on immature red 
cells and thus, the level of bone marrow erythropoieisis (Cazzola et al, 1992) 
It has been shown that, as compared to normal individuals, levels are marginally 
increased in nonanaemic iron-deficient subjects but more dramatically so in patients with 
IDA (Punnonen et al, 1997). In such patients, sTfR. levels exhibit strong correlations with 
various red cell indices indicative of iron deficiency and are inversely related to serum 
ferritin (Olivares et al, 2000). 
Skikne et al in 1990 have published a study on the clinical utility of sTfR. as a marker of 
the iron status. When normal volunteers underwent graded phlebotomy, ferritin decreased 
progressively while sTfR did not change much during the phase of storage iron depletion. 
However, sTfR increased significantly when marrow functional iron deficiency and 
anaemia developed. Hence, the iron status may be fully assessed by using serum ferittin 
as a measure of iron storage (storage iron depletion), sTfR. as a measure of functional 
tissue iron deficiency (iron deficient erythropoiesis), and Hb as a measure of advanced 
iron deficiency (IDA). Because of the reciprocal relationship between sTfR and ferritin 
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measurements, the ratio of sTtR/ferritin describes a perfect log-linear relationship to body 
iron over a wide range of normal and depleted iron stores (Skikne et a/, 1990). 
This can also be obtained by the log of the ratio of sTfR to ferritin or by the sTiR-ferritin 
index, the ratio of sTfR to log ferritin. These ratios increase the sensitivity of sTfR in 
detecting latent iron deficiency (Mal ope et al, 2001 ). 
2.5.5 Erythropoietin 
Measurement of erythropoietin levels is useful only for anaennc patients with 
haemoglobin level of less than 1 Og per deciliter. This is because the erythropoietin level 
at higher haemoglobin concentrations remains in the normal range. 
Erythropoietin levels have been analyzed for their predictive value with respect to 
treatment of ACD with erythropoietic agents (Ludwig eta/, 1994) 
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CHAPTER3 
OBJECTIVES 
3.0. OBJECTIVES OF THE STUDY 
3.1. General objective 
1. To detect coexisting iron deficiency anemia in patients with anaemia of 
chronic disease and to compare the haematological parameters between 
the control and the anaemia of chronic disease patients. 
3.2. Specific objectives 
i. To identify iron deficiency in patients with anaemia of chronic disease 
using serum ferritin, soluble transferrin receptor (sTfR) and transferrin 
receptor- ferritin index ( TfR- F index) 
n. To determine the agreement between the TfR- F index and sTfR in 
detecting iron deficiency 
iii. To correlate the sTfR value with other haematological parameters in 
patients with coexisting IDA. 
iv. To correlate sTfR value with age and sex in the control group. 
v. To compare the haematological parameters between the IDA and non-
IDA group determined by sTtR. and transferrin receptor-ferritin index 
(TtR-F index) 
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CHAPTER4 
METHODOLOGY 
4.0 METHODOLOGY 
4.1. Study design 
This case control study was conducted over a one year period from November 2004 till 
November 2005 at Hospital Universiti Sains Malaysia. Protocol for this study was 
approved by the School of Medical Science Research and Ethical Committee. All 
subjects gave written consent. 
4.2 Sampling for cases 
4.2.1 Source population for cases 
The source population of the subjects was those who attended Medical Clinic, Hospital 
Universiti Sains Malaysia November 2004 till November 2005 who was diagnosed as 
having anaemia of chronic diseases. The chronic diseases included in this study were 
chronic infections, autoimmune diseases and chronic kidney diseases. 
4.2.2 Sampling frame for cases 
The sampling frame was those who were diagnosed as having anaemia of chronic 
diseases mentioned above and fulfill the inclusion and exclusion criteria. 
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4.2.3 Inclusion criteria for eases 
The inclusion criteria were patients who had the haemoglobin of less than ll.Sg/dl for 
female, less than 13.5g/dl for male (according to WHO criteria for anaemia), mean 
corpuscular volume of less than 95ft and confirmed diagnosis of having anaemia of 
chronic disease. The diagnosis was confirmed by history, physical examination and 
laboratory tests done by the managing doctor. 
4.2.4 Exclusion criteria for cases 
The exclusion criteria were those who were diagnosed as having thalassaemia major, iron 
deficiency anaemia, megaloblastic anaemia and hematological malignancy, had previous 
blood transfusion in the preceding month and those on treatment with oral or parenteral 
iron. All the above data were obtained from the patients' clinical records. 
4.2.5 Sampling method for cases 
Purposive sampling was carried out for cases. All those who fulfill the criteria mentioned 
were included. A total of 60 patients were included in this study. The flow chart is 
shown in Figure 1.0 
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Identification of cases from Medical clinics 
Clinical and laboratory di osis to confirm anaemia of chronic disease ACD 
No evidence of ACD (n=O) Confirmed ACD (n=60) 
l l 
Exclude Further tests 
Fulfill the inclusion and exclusion criteria 
l 
Written consent 
Recruited into the study (n=60) 
Figure 1.0 Flowchart of sampling methods for cases 
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